Illumina's Q3 Revenues Jump 50 Percent on Strength of HiSeq | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina reported after the close of the market Tuesday that its third-quarter revenues jumped 50 percent, easily beating analysts' consensus estimate.

The San Diego-based sequencing and array technologies firm reported total revenues of $237.3 million for the three-month period ended Oct. 3, compared to $158.4 million for the third quarter of 2009. Analysts had expected the firm to post revenues of $218.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.